AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16423743 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 ms exposure duration
Number of subjects: 0
Study 14644719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily (n = 90)
Number of subjects: 177
Study 14644719 — intervention group
Group type: COMPARATOR
Intervention: Combined timolol 0.5% and dorzolamide 2% twice daily (n = 87)
Number of subjects: 177
Study 10942744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐AAT pacing (simultaneous right and left atrial triggered pacing at a rate of >/=85 bpm)
Number of subjects: 118
Study 10942744 — intervention group
Group type: COMPARATOR
Intervention: RA‐AAI pacing (right atrial pacing at 45 bpm)
Number of subjects: 118
Study 10942744 — intervention group
Group type: COMPARATOR
Intervention: RA‐AAT pacing (right atrial triggered pacing at a rate of >/=85 bpm)
Number of subjects: 118
Study 8821686 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm irrigant (37 degrees C from level-one fluid warmer)
Number of subjects: 28
Study 8821686 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm irrigant (35 degrees C from Ohio Servocare incubator)
Number of subjects: 28
Study 8821686 — intervention group
Group type: COMPARATOR
Intervention: Cold irrigant (17 degrees C)
Number of subjects: 28
Study 1450626 — intervention group
Group type: EXPERIMENTAL
Intervention: High diastolic blood pressure group
Number of subjects: 78
Study 1450626 — intervention group
Group type: COMPARATOR
Intervention: Low diastolic blood pressure group
Number of subjects: 78
Study 6366664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 101
Study 6366664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 101
Study 6366664 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone and Cefoxitin (both regimens)
Number of subjects: 101
Study 6366664 — intervention group
Group type: COMPARATOR
Intervention: Major postoperative infection
Number of subjects: 101
Study 30265294 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Reminder Information and Social Management (PRISM) system
Number of subjects: 150
Study 29506580 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting antiplatelet drugs
Number of subjects: 720
Study 29506580 — intervention group
Group type: COMPARATOR
Intervention: Avoiding antiplatelet drugs
Number of subjects: 720
Study 27461440 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 440
Study 27461440 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 440
Study 24678807 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol combined with nifedipine (30 mg/d nifedipine + 20 mg/d arotinolol)
Number of subjects: 152
Study 24678807 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol combined with amlodipine (5 mg/d amlodipine + 20 mg/d arotinolol)
Number of subjects: 152
Study 24678807 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol combined with felodipine (5 mg/d felodipine + 20 mg/d arotinolol)
Number of subjects: 152
Study 21798784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention with a pharmacist explaining prescribed drugs and providing a personalized medication timetable
Number of subjects: 100
Study 21798784 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice (Control group)
Number of subjects: 100
Study 21798784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention with a pharmacist
Number of subjects: 100
Study 21308266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body interventions (including yoga, relaxation, Tai Chi Chih, and music)
Number of subjects: 12
Study 21308266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 12
Study 21308266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body interventions (general)
Number of subjects: 12
Study 18506965 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling technique with mother as model (Group A)
Number of subjects: 155
Study 18506965 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling technique with father as model (Group B)
Number of subjects: 155
Study 18506965 — intervention group
Group type: COMPARATOR
Intervention: Tell show do approach (Group C)
Number of subjects: 155
Study 16118067 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 1351
Study 16118067 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 1351
Study 12113387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask proportional assist ventilation (PAV)
Number of subjects: 33
Study 12113387 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 33
Study 12113387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PAV and SB)
Number of subjects: 33
Study 10081699 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone analogue (LH-RHa) started the first day of radiotherapy and administered every 4 weeks over 3 years
Number of subjects: 0
Study 10081699 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone analogue (LH-RHa) initiated in the last week of radiation therapy and continued until relapse
Number of subjects: 0
Study 10081699 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression prior to and during radiation
Number of subjects: 0
Study 10081699 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy with LH-RHa during and after radiation
Number of subjects: 0
Study 8608360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 8608360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 0
Study 8608360 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 0
Study 8608360 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 0
Study 8608360 — intervention group
Group type: COMPARATOR
Intervention: Salmon calcitonin therapy
Number of subjects: 0
Study 2200187 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 5000 IU + 0.5 mg DHE (HDHE) three times a day
Number of subjects: 404
Study 2200187 — intervention group
Group type: COMPARATOR
Intervention: Acetyl‐salicylic‐acid (ASA) 0.5 g + dihydroergotamin (DHE) 2.5 mg three times a day
Number of subjects: 404
Study 7082024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% crude coal tar in an absorbent ointment base (Aquaphor)
Number of subjects: 17
Study 7082024 — intervention group
Group type: COMPARATOR
Intervention: Absorbent ointment base alone
Number of subjects: 17
Study 31208191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer prevention education program (two 40-minute sessions)
Number of subjects: 0
Study 31208191 — intervention group
Group type: COMPARATOR
Intervention: Music video about cancer prevention (control group)
Number of subjects: 0
Study 26880758 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing accelerometers
Number of subjects: 38
Study 26880758 — intervention group
Group type: COMPARATOR
Intervention: Not wearing accelerometers
Number of subjects: 38
Study 26549533 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305
Study 26549533 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305
Study 26549533 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-predictor model
Number of subjects: 2305
Study 26549533 — intervention group
Group type: COMPARATOR
Intervention: 14-predictor Seattle model
Number of subjects: 2305
Study 24672940 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medical decoction
Number of subjects: 81
Study 24672940 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir and pidotimod
Number of subjects: 81
Study 22037127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 13
Study 19911325 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured telephone aftercare
Number of subjects: 527
Study 19911325 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐directive telephone aftercare
Number of subjects: 527
Study 19911325 — intervention group
Group type: COMPARATOR
Intervention: No aftercare (control group)
Number of subjects: 527
Study 17326083 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA2 patients
Number of subjects: 15
Study 17326083 — intervention group
Group type: EXPERIMENTAL
Intervention: MSA‐C patients
Number of subjects: 15
Study 17326083 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 15
Study 17326083 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA2 and MSA‐C patients
Number of subjects: 15
Study 15147247 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 75
Study 15147247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 15147247 — intervention group
Group type: COMPARATOR
Intervention: Frovatriptan 2.5 mg and Placebo
Number of subjects: 75
Study 12352234 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg three times daily for seven days
Number of subjects: 38
Study 12352234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12352234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 9839847 — intervention group
Group type: COMPARATOR
Intervention: C: 25 g creatine monohydrate/day, 5 days
Number of subjects: 12
Study 9839847 — intervention group
Group type: COMPARATOR
Intervention: CC: 25 g creatine monohydrate/day, 5 days plus 5 g/h during exercise
Number of subjects: 12
Study 9839847 — intervention group
Group type: EXPERIMENTAL
Intervention: P: Placebo
Number of subjects: 12
Study 8301790 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg nicotine patch therapy with intensive group counseling for 8 weeks (Study 1)
Number of subjects: 200
Study 8301790 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg nicotine patch therapy for 4 weeks followed by 11-mg nicotine patch therapy for 2 weeks with brief individual counseling (Study 2)
Number of subjects: 200
Study 8301790 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg nicotine patch therapy
Number of subjects: 200
Study 8301790 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 200
Study 2494246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 290
Study 2494246 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 290
Study 2494246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained reperfusion
Number of subjects: 290
Study 2494246 — intervention group
Group type: COMPARATOR
Intervention: Nonsustained reperfusion
Number of subjects: 290
Study 31496425 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y‐IT consolidation
Number of subjects: 75
Study 31496425 — intervention group
Group type: COMPARATOR
Intervention: Rituximab maintenance
Number of subjects: 75
Study 28659181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and ifosfamide with or without paclitaxel
Number of subjects: 45
Study 25981847 — intervention group
Group type: EXPERIMENTAL
Intervention: High proactive coping (physicians in the highest quartile)
Number of subjects: 1502
Study 25981847 — intervention group
Group type: EXPERIMENTAL
Intervention: High MSTAT (physicians in the highest quartile)
Number of subjects: 1502
Study 25981847 — intervention group
Group type: EXPERIMENTAL
Intervention: High Need for Cognition (physicians in the highest quartile)
Number of subjects: 1502
Study 25981847 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anxiety (physicians in the lowest quartile)
Number of subjects: 1502
Study 25981847 — intervention group
Group type: EXPERIMENTAL
Intervention: High proactive coping (adjusted odds ratio)
Number of subjects: 1502
Study 25981847 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anxiety (adjusted odds ratio)
Number of subjects: 1502
Study 23695806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m-HDP-SPECT/CT analysis
Number of subjects: 100
Study 21955830 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural block
Number of subjects: 48
Study 21955830 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural block
Number of subjects: 48
Study 19921357 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 1 mg kg(‐1) before surgery
Number of subjects: 44
Study 19921357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lipid emulsion 0.1 ml kg(‐1)) before surgery
Number of subjects: 44
Study 17010568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (CSM) therapy for 2 weeks
Number of subjects: 26
Study 17010568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (CSM) therapy reinstated for 2 weeks
Number of subjects: 26
Study 17010568 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy for 2 weeks
Number of subjects: 26
Study 17010568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (CSM) therapy after placebo
Number of subjects: 26
Study 17010568 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to WDBs
Number of subjects: 26
Study 17010568 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of MMP9, leptin, VEGF
Number of subjects: 26
Study 17010568 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of MMP9, leptin, VEGF at Time Point 5
Number of subjects: 26
Study 17010568 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with abnormal levels of MMP9, leptin, VEGF, pulmonary function at Time Point 5
Number of subjects: 26
Study 15516022 — intervention group
Group type: COMPARATOR
Intervention: Single-dose CF101 (1, 5, or 10 mg)
Number of subjects: 43
Study 15516022 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose CF101 (2, 3, 4, or 5 mg, 12-hourly for 7 days)
Number of subjects: 43
Study 15516022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose CF101 (5 mg)
Number of subjects: 43
Study 15516022 — intervention group
Group type: EXPERIMENTAL
Intervention: First multiple-dose CF101 (5 mg)
Number of subjects: 43
Study 15516022 — intervention group
Group type: EXPERIMENTAL
Intervention: After 7 days of multiple dosing
Number of subjects: 43
Study 15516022 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate increase after CF101
Number of subjects: 43
Study 15516022 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocytosis after CF101 (5 and 10 mg)
Number of subjects: 43
Study 15689068 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (3.3 mg/kg on day 1, followed by 1.65 mg/kg for the next four days, total dose = 600 mg)
Number of subjects: 42
Study 15689068 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate followed by primaquine (15 mg for 14 days)
Number of subjects: 42
Study 10615228 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-patient discussions about RCTs
Number of subjects: 82
Study 7785999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (n = 43)
Number of subjects: 90
Study 7785999 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (n = 47)
Number of subjects: 90
Study 2195054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 20
Study 272945 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐asparaginase 1,000 mu/kg iv q.d. x 10, vincristine 2.0 mg/m2 iv q.w. x 4 and prednisone 40 mg/m2 p.o.q.d. x 28 days
Number of subjects: 227
Study 272945 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combinations of cytosine arabinoside, cyclophosphamide, vincristine, prednisone, BCNU or CCNU
Number of subjects: 227
Study 272945 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU or CCNU
Number of subjects: 227
Study 27909178 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine inquiry about violence victimization and empowering strategies
Number of subjects: 1051
Study 27909178 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine inquiry about violence victimization
Number of subjects: 1051
Study 27909178 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaires about victimization after the visit)
Number of subjects: 1051
Study 27909178 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimized young women in the intervention group
Number of subjects: 1051
Study 31181088 — intervention group
Group type: EXPERIMENTAL
Intervention: Active education policy promoting inclusion since 2005
Number of subjects: 0
Study 31181088 — intervention group
Group type: EXPERIMENTAL
Intervention: Schools in Afghanistan
Number of subjects: 0
Study 27730325 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dexamethasone nasal spray
Number of subjects: 0
Study 27730325 — intervention group
Group type: EXPERIMENTAL
Intervention: Device using pressure and vibration to distribute steroid aerosol endonasally
Number of subjects: 0
Study 25109276 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint left ventricular pacing (MPP)
Number of subjects: 44
Study 25109276 — intervention group
Group type: COMPARATOR
Intervention: Conventional left ventricular pacing (CONV)
Number of subjects: 44
Study 25092886 — intervention group
Group type: EXPERIMENTAL
Intervention: HRM diet (300 g/day lean red meat)
Number of subjects: 23
Study 25092886 — intervention group
Group type: EXPERIMENTAL
Intervention: HRM+HAMSB diet (HRM with 40 g/day butyrylated high amylose maize starch)
Number of subjects: 23
Study 22561907 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator
Number of subjects: 495
Study 22561907 — intervention group
Group type: COMPARATOR
Intervention: PCPT model
Number of subjects: 495
Study 22561907 — intervention group
Group type: COMPARATOR
Intervention: PSA threshold of 4 ng ml(‐1)
Number of subjects: 495
Study 19486621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 739
Study 19486621 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 739
Study 17692112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (OAT)
Number of subjects: 701
Study 17692112 — intervention group
Group type: EXPERIMENTAL
Intervention: No antithrombotic therapy (AT)
Number of subjects: 701
Study 17692112 — intervention group
Group type: EXPERIMENTAL
Intervention: OAT prescription in 2004
Number of subjects: 701
Study 15351853 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied aprotinin (1.0 x 10(6) KIU)
Number of subjects: 44
Study 15351853 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution (control group)
Number of subjects: 44
Study 15351853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (6.0 x 10(6) KIU) systemically for both groups
Number of subjects: 44
Study 11110645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (inl) immunization with monovalent, live attenuated, cold‐adapted recombinant (CR) or inactivated influenza virus (MIV) vaccine
Number of subjects: 12
Study 11110645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inl (CR or MIV) and im vaccine
Number of subjects: 12
Study 11110645 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (im) immunization with MIV
Number of subjects: 12
Study 11110645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9701860 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for assuring adherence (individual)
Number of subjects: 39
Study 9701860 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for assuring adherence (family support)
Number of subjects: 39
Study 9701860 — intervention group
Group type: COMPARATOR
Intervention: Medication information procedure
Number of subjects: 39
Study 8023663 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 75 micrograms.kg-1 followed by continuous infusion of propofol
Number of subjects: 80
Study 8023663 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1.5 mg.kg-1 bolus followed by infusion
Number of subjects: 80
Study 2688396 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed bean flakes meal
Number of subjects: 6
Study 2688396 — intervention group
Group type: COMPARATOR
Intervention: Potato flakes meal
Number of subjects: 6
Study 31003677 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% grape seed extract ointment
Number of subjects: 129
Study 31003677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% grape seed extract ointment
Number of subjects: 129
Study 31003677 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 129
Study 28550709 — intervention group
Group type: EXPERIMENTAL
Intervention: High heart rate in patients with abnormal renal function
Number of subjects: 3923
Study 28550709 — intervention group
Group type: EXPERIMENTAL
Intervention: High heart rate in patients with normal renal function
Number of subjects: 3923
Study 28550709 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10 bpm increase of heart rate
Number of subjects: 3923
Study 24983681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction at 38 weeks of gestation
Number of subjects: 31169
Study 24983681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction at 39 weeks of gestation
Number of subjects: 31169
Study 24983681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction at 40 weeks of gestation
Number of subjects: 31169
Study 24983681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction
Number of subjects: 31169
Study 24983681 — intervention group
Group type: COMPARATOR
Intervention: Expectant treatment
Number of subjects: 31169
Study 23413265 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 1669
Study 23413265 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted use of N95 respirators
Number of subjects: 1669
Study 23413265 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 1669
Study 23413265 — intervention group
Group type: COMPARATOR
Intervention: Continuous use of N95 respirators
Number of subjects: 1669
Study 21545991 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 420
Study 21545991 — intervention group
Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 420
Study 19262754 — intervention group
Group type: EXPERIMENTAL
Intervention: FMP1/AS02 (50 microg)
Number of subjects: 400
Study 19262754 — intervention group
Group type: COMPARATOR
Intervention: Rabipur(R) rabies vaccine
Number of subjects: 400